Takeda Pharmaceutical Co. Ltd. and India's Zydus Cadila have announced a "broad-based" agreement to develop a vaccine for chikungunya. The deal encompasses early stage development to final commercialization of the vaccine, but no specifics on each partner's role or their financial commitments were provided.
The chikungunya virus is transmitted via the Aedes aegypti and Aedes albopictus mosquitoes - the same vectors that spread dengue...






